Meglumine antimonate

Meglumine antimonate

Gene therapy
Clinical data
AHFS/Drugs.com	Micromedex Detailed Consumer Information
ATC code	P01CB01 (WHO) Template:ATCvet
Physiological data
Legal status
Pharmacokinetic data
Identifiers
IUPAC name Hydroxy-dioxostiborane; (2R,3R,4R,5S)-6-methylaminohexane-1,2,3,4,5-pentol
CAS Number	133-51-7 N
PubChem Template:Abbreviation	64953
ChemSpider	58479 Y
ChEMBL	ChEMBL239129 Y
NIAID ChemDB	008733
Chemical and physical data
Formula	Variable
Molar mass	Variable
3D model (JSmol)	Interactive image
SMILES O=[Sb](=O)O.O[C@@H]([C@@H](O)[C@H](O)[C@@H](O)CNC)CO
InChI InChI=1S/C7H17NO5.H2O.2O.Sb/c1-8-2-4(10)6(12)7(13)5(11)3-9;;;;/h4-13H,2-3H2,1H3;1H2;;;/q;;;;+1/p-1/t4-,5+,6+,7+;;;;/m0..../s1 Y Key:XOGYVDXPYVPAAQ-SESJOKTNSA-M Y
Template:XmarkY (what is this?)  (verify)

WikiDoc Resources for Meglumine antimonate
Articles
Most recent articles on Meglumine antimonate Most cited articles on Meglumine antimonate Review articles on Meglumine antimonate Articles on Meglumine antimonate in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Meglumine antimonate Images of Meglumine antimonate Photos of Meglumine antimonate Podcasts & MP3s on Meglumine antimonate Videos on Meglumine antimonate
Evidence Based Medicine
Cochrane Collaboration on Meglumine antimonate Bandolier on Meglumine antimonate TRIP on Meglumine antimonate
Clinical Trials
Ongoing Trials on Meglumine antimonate at Clinical Trials.gov Trial results on Meglumine antimonate Clinical Trials on Meglumine antimonate at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Meglumine antimonate NICE Guidance on Meglumine antimonate NHS PRODIGY Guidance FDA on Meglumine antimonate CDC on Meglumine antimonate
Books
Books on Meglumine antimonate
News
Meglumine antimonate in the news Be alerted to news on Meglumine antimonate News trends on Meglumine antimonate
Commentary
Blogs on Meglumine antimonate
Definitions
Definitions of Meglumine antimonate
Patient Resources / Community
Patient resources on Meglumine antimonate Discussion groups on Meglumine antimonate Patient Handouts on Meglumine antimonate Directions to Hospitals Treating Meglumine antimonate Risk calculators and risk factors for Meglumine antimonate
Healthcare Provider Resources
Symptoms of Meglumine antimonate Causes & Risk Factors for Meglumine antimonate Diagnostic studies for Meglumine antimonate Treatment of Meglumine antimonate
Continuing Medical Education (CME)
CME Programs on Meglumine antimonate
International
Meglumine antimonate en Espanol Meglumine antimonate en Francais
Business
Meglumine antimonate in the Marketplace Patents on Meglumine antimonate
Experimental / Informatics
List of terms related to Meglumine antimonate

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Meglumine antimoniate (or meglumine antimonate) is a medicine used for treating leishmaniasis. It is manufactured by Aventis and sold as Glucantime in France, and Glucantim in Italy. It belongs to a group of compounds known as the pentavalent antimonials. It is administered by intramuscular injection.

See also

• Meglumine

References

Template:Antiinfective-drug-stub